SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Chip

Chip is experiencing intense volatility and trading volume as investors debate its long-term potential as an AI-focused infrastructure token versus concerns regarding insiders and potential pump-and-dump activity. The community is actively discussing the impact of its rapid listing on major brokerages and closely monitoring price action for signs of a squeeze.

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Terra Luna Classic remains a subject of intense community debate, with proponents pointing to consistent monthly token burns by Binance and ecosystem developments like the LUNCVERSE as catalysts for a potential long-term recovery. Meanwhile, skeptics continue to label the asset a failed project, highlighting ongoing volatility and lingering sentiment from the original ecosystem collapse as key reasons for caution.

Airgain, Inc. provides embedded antenna products, integration support and test services. The firm works in partnership with the entire ecosystem, including carriers, chipset suppliers, OEMs, and ODMs. Its products include embedded, external and carrier-class antennas. The company offers custom antenna design and performance validation services. Its antennas are deployed in carrier, fleet, enterprise, residential, private, government, and public safety wireless networks and systems, including set-top boxes, access points, routers, modems, gateways, media adapters, and asset tracking devices. The company was founded on March 20,1995 and is headquartered in San Diego, CA.

Airgain Inc

Airgain Inc is trending following news of a multi-million dollar design win with a major U.S. utility to deploy its wireless connectivity technology across its fleet. Investors are actively discussing the potential impact of this contract and whether the company can maintain this momentum to drive long-term revenue growth.

Orca is the most user-friendly DEX on Solana.  Orca is one of the first general-purpose AMMs launched on Solana. Users can swap assets, provide liquidity, and earn yield through an easy-to-use interface. Projects can use Orca as a money-lego to easily integrate swapping, farming, or on-chain data into their dApp.  Orca strives to provide easy and effective financial tools for everyone, bringing DeFi to the masses.

Orca

Orca is trending as traders discuss a potential short squeeze and high-volume price surge, with many speculating on the impact of upcoming governance proposals and Solana ecosystem growth. Community sentiment remains divided between those aggressively accumulating the asset for its perceived low-float upside and skeptics who are monitoring for signs of profit-taking or volatility.

FLOKI is a community-driven, multi-chain utility token that powers a broad ecosystem including decentralized gaming, finance, and educational platforms. Originally evolving from a meme-based asset, the project now focuses on a utility-driven model centered around three pillars: community engagement, technical utility, and global charity work, balancing this ecosystem growth with social impact, such as building schools in developing nations like Ghana and Nigeria.  Key features include Valhalla, an NFT metaverse game where the token serves as the primary currency for capturing creatures and upgrading characters. The ecosystem also features the FlokiFi Locker for securing digital assets and the University of FLOKI for web3 education,with real-world integration facilitated through a prepaid debit card for everyday purchases at global stores. Staking FLOKI allows users to earn rewards in a sister token.  The project is led by a group of core advisors known by pseudonyms such as Sabre and B (The Viking) and is officially backed by DWF Labs, a major digital asset investment firm and market maker. While a small tax on decentralized trades helps fund development, value moves through the system as users utilize the token to pay for in-game items, access asset-locking services, or purchase merchandise.

Floki Token

Floki is currently generating significant community buzz as investors focus on its expansion into institutional finance through ETP listings and ongoing ecosystem developments like the Valhalla metaverse. Supporters are actively discussing the token's potential for a broader meme sector rally, often highlighting its historical trend patterns and anticipation of future liquidity cycles.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is currently sparking intense debate within the community, with many investors actively accumulating during the current price consolidation while others express frustration over the lack of major project milestones and price momentum. Sentiment remains deeply polarized between those maintaining long-term conviction in the project's utility and those concerned by the significant lag in performance compared to broader market trends.

Silicon Motion Technology Corp. engages in the development, manufacture, and supply of semiconductor products for the electronics market. Its products include Flash Controllers, Storage Solutions, and others. It offers embedded and expandable storage, radio frequency integrated circuits and embedded graphics. The company was founded in November 1995 and is headquartered in Hong Kong.

Silicon Motion Technology Corp - ADR

Silicon Motion Technology Corp.

Silicon Motion is seeing significant volatility and investor interest following news that Chinese regulators have conditionally cleared its long-standing merger deal with MaxLinear. The community is actively debating the implications of the acquisition's path forward, with traders closely monitoring the spread between the current price and the deal's implied value as they navigate heightened volume and regulatory uncertainty.

Lantheus Holdings, Inc. engages in the provision of diagnostic imaging and nuclear medicine products. The firm develops products that help healthcare professionals in patient management and outcomes and assists clinicians with the detection of cardiovascular disease. It operates through the U.S. and International geographical segments. The U.S. segment produces and markets products, radiopharmacies, PMFs, integrated delivery networks, hospitals, clinics, and group practices throughout the United States. The International segment offers direct distribution in Canada and third-party distribution relationships in Europe, Canada, Australia, Asia-Pacific, Central America, and South America. The company was founded in 1956 and is headquartered in Bedford, MA.

Lantheus Holdings Inc

Lantheus Holdings is currently trending as investors focus on its strategic expansion into radiopharmaceuticals, bolstered by its significant equity stake in Radiopharm Theranostics and recent portfolio acquisitions. The community is actively discussing the potential for a larger buyout of smaller radiopharma players as Lantheus aims to consolidate its leadership in cancer diagnostics and therapeutics.

Simulations Plus, Inc. engages in the provision of software and consulting services supporting drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. The firm operates through the Software and Services segment. The Software segment offers software products for pharmaceutical research, development, and commercialization of the firm's products. The Services segment focuses on contracted consulting studies for customers and offers services supporting marketplace insight and medical communications for clinical and commercial drug development. The company was founded by Walter S. Woltosz and Virginia E. Woltosz on July 17, 1996 and is headquartered in Durham, NC.

Simulations Plus Inc.

Simulations Plus is trending as investors monitor its recent fiscal performance and strategic focus on integrating AI into drug development processes. The community is actively discussing the company's role as a niche healthcare AI player and evaluating the balance between its long-term growth potential in biosimulation and broader industry market volatility.

KAT is a defi token with governance-like mechanics for Katana.  It is designed to function as a lever for directing capital: users that lock KAT receive a voting version of KAT — vKAT — in return. vKAT underpins key aspects of the chain’s economy, providing rewards to those users that participate. these fee-based rewards function as an incentive for KAT holders to engage in cooperative, positive-sum behavior.

Katana

Katana is gaining significant attention following the adoption of a new ve-style tokenomics system aimed at enhancing DeFi liquidity and accrual across the network. Community sentiment remains polarized as participants monitor recent volatility and technical consolidation while weighing the potential impact of future ecosystem developments.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Receives Average Rating of "Moderate Buy" from Brokerages

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the six analysts that are covering the company, MarketBeat.com reports. One...

DiaMedica Therapeutics Highlights DM199 Preeclampsia Data, Stroke Interim Catalyst at RedChip Conference

DiaMedica Therapeutics (NASDAQ:DMAC) President and CEO Rick Pauls outlined the company's development programs for its lead candidate, DM199, during a presentation at the RedChip Biotech Investor...

Q1 EPS Estimate for DiaMedica Therapeutics Raised by Analyst

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC - Free Report) - Stock analysts at HC Wainwright raised their Q1 2026 earnings per share estimates for DiaMedica Therapeutics in a report released on Wednesday, April 1st. HC Wainwright analyst M. Caufield now forecasts that the company will earn ($0.17) per...

HC Wainwright Issues Pessimistic Estimate for DMAC Earnings

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC - Free Report) - Research analysts at HC Wainwright reduced their FY2029 EPS estimates for DiaMedica Therapeutics in a research note issued to investors on Wednesday, April 1st. HC Wainwright analyst M. Caufield now expects that the company will post earning...

DiaMedica Therapeutics Q4 Earnings Call Highlights

DiaMedica Therapeutics (NASDAQ:DMAC) executives used the company's fiscal 2025 earnings call on Monday to highlight clinical progress for its lead asset DM199 and review an improved year-end cash position following financing activity in 2025.

DM199 mechanism and pipeline focus
President and CEO Ric...

DiaMedica Therapeutics (NASDAQ:DMAC) Posts Earnings Results, Beats Expectations By $0.02 EPS

DiaMedica Therapeutics (NASDAQ:DMAC - Get Free Report) posted its quarterly earnings data on Monday. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.02...

DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia (PE), fetal growth restriction (FGR), and acute ischemic...

Top Wall Street Forecasters Revamp DiaMedica Therapeutics Expectations Ahead Of Q4 Earnings

DiaMedica Therapeutics (NASDAQ: DMAC) will release Q4 earnings on March 30. Analysts expect a quarterly loss of 18 cents per share. Stock fell 0.9% on Friday.read more...

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Given Average Rating of "Moderate Buy" by Brokerages

Shares of DiaMedica Therapeutics, Inc. (NASDAQ:DMAC - Get Free Report) have received a consensus rating of "Moderate Buy" from the six brokerages that are covering the firm, MarketBeat Ratings...

DiaMedica Therapeutics (DMAC) Projected to Post Earnings on Tuesday

DiaMedica Therapeutics (NASDAQ:DMAC) will be releasing its Q4 2025 earnings on Tuesday, March 31. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-3-31-diamedica-therapeutics-inc-stock...

DiaMedica Therapeutics, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. It develops the DM199 product candidate, which focuses on acute ischemic stroke (AIS) and chronic kidney disease (CKD). The company was founded by Wayne Lautt on January 21, 2000 and is headquartered in Minneapolis, MN.

DMAC
DiaMedica Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest DMAC News

DMACDiaMedica Therapeutics Inc